We’ve got the Centers for Medicare & Medicaid Services’ (CMS) most recent list of Medicare Part B drugs your clients may pay reduced coinsurance for from January through March 2026!
CMS publishes the Medicare Part B rebatable drugs quarterly. Keep reading to see the latest Part B rebate guidance.
Inflation-Adjusted Coinsurances for Medicare Part B Drugs
As a reminder, Medicare Part B generally covers drugs provided in doctors’ offices and hospital outpatient departments. Part B drugs may qualify for price adjustments as a result of the Medicare Prescription Drug Inflation Rebate provision in the Inflation Reduction Act (IRA).
The provision states that drug manufacturers who increase the prices of their drugs faster than the rate of inflation must reimburse Medicare for the difference. The reimbursement comes in the form of a rebate, hence the name “Part B rebatable drugs.”
CMS then passes the savings back to Medicare enrollees through inflation-adjusted Part B coinsurances.
Rebatable Part B Drugs with Reduced Coinsurance for 2026
Recently, CMS published their January 2026 ASP Pricing File, noting the 91 Part B prescription drugs that may have lower beneficiary coinsurance rates for January, February, and March due to their prices increasing faster than inflation.
Note: CMS releases information on inflation-adjusted coinsurances via their quarterly Average Sales Price (ASP) public files. Occasionally, CMS updates these after they release them, before the changes go into effect.
Q1 2026 Part B Rebatable Drugs
Source: CMS.gov
For more info on the Medicare Prescription Drug Rebate Program, visit CMS.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare.
Not affiliated with or endorsed by Medicare or any government agency.
Share Post